Core 1: Biospecimen and Pathology Core

核心1生物标本和病理学：总结/摘要 生物标本和病理学核心将协调与收集、处理、储存和 为所有SPORE项目分发注释的人类和小鼠生物标本，包括职业 增强计划（CEP）和发展研究计划（DRP）。核心将由两名 全国知名的胃肠道/胰腺病理学家Dipen Maru博士和Huamin Wang博士。人类 生物标本，核心将与MDACC机构组织库（ITB）接口。生物标本资源 包括新鲜采集/速冻和福尔马林固定石蜡 来自2500多例切除的肝结直肠转移瘤的包埋肿瘤和正常标本（包括 TMAs），新鲜收集并速冻334例患者的腺瘤，福尔马林固定石蜡包埋 来自870例或更多散发性腺瘤或家族性腺瘤性息肉病患者的标本。现有 胰腺库中可用的生物标本资源和相关IRB批准的方案包括新鲜的 从胰管维普莱切除术中采集/快速冷冻的肿瘤和正常组织样本 腺癌232例，福尔马林固定石蜡包埋标本，另外672例 患者，包括来自胰腺导管腺癌和导管内胰腺癌的组织微阵列， 粘液性肿瘤核心将通过协调前瞻性采血来支持项目1， 低温保存和运输。具体来说，核心教师将前瞻性地收集，处理和 在获得镜像图像后分配来自肝结直肠转移的新鲜肿瘤和正常样本 组织学质量控制部分。核心将提供福尔马林固定石蜡包埋的正常， 腺瘤和癌到项目2。此外，核心将提供生物标本鉴定服务， 包括但不限于用STAT 3处理的人和鼠组织的组织病理学表征 抑制剂和免疫组织化学染色和解释，包括通过 在CLIA认证的设施中进行自动图像分析。核心将提供新鲜切除的PDAC样本， 用于项目3的患者来源的异种移植物和离体活组织敏感性测定（LTSA）。此外，核心将 提供组织病理学表征，免疫组织化学服务和解释指南， 来自正在进行的联合临床试验的临床前样本，以及从两个组织中获得的系列组织活检， 正在进行的临床试验项目3.该中心还将协调分发适当的样品， 研究人员通过SPORE CEP和DRP赠款资助。核心人员沿着ITB将 输入与生物标本采集、处理、鉴定、分发的所有过程相关的详细信息 和分析物提取到被称为“组织站”的机构生物样本信息平台中。的 核心活动将增强组织站的这些功能，并设计新的界面 专门针对组织站中的GI孢子。

CORE 1 BIOSPECIMEN AND PATHOLOGY: Summary/Abstract The Biospecimen and Pathology Core will coordinate efforts related to collection, processing, storage and distribution of annotated human and murine biospecimens for all of the SPORE projects, including the Career Enhancement Program (CEP) and Developmental Research Program (DRP). The Core will be co-led by two nationally reputed gastrointestinal/pancreatic pathologists, Drs. Dipen Maru and Huamin Wang. For human biospecimens, the core will interface with the MDACC Institutional Tissue Bank (ITB). Biospecimen resources from the lower gastrointestinal tissue bank include freshly collected/snap frozen and formalin fixed paraffin embedded tumor and normal specimens from more than 2500 resected hepatic colorectal metastases (including TMAs), freshly collected and snap frozen adenoma from 334 patients and formalin fixed paraffin embedded specimens from 870 or more patients with sporadic adenoma or familial adenomatous polyposis. Existing biospecimen resources available in the pancreatic bank and related IRB approved protocols include freshly collected/snap frozen tumor and normal tissue sample from Whipple resection for pancreatic ductal adenocarcinoma from 232 patients, with formalin fixed paraffin embedded specimens and additional 672 patients, including tissue microarrays from pancreatic ductal adenocarcinoma and intraductal pancreatic mucinous neoplasms. The Core will support Project 1 by coordinating prospective blood collection, cryopreservation and transport with the ITB. Specifically, Core faculty will prospectively collect, process and distribute fresh tumor and normal samples from hepatic colorectal metastases after obtaining mirror image section for histology quality control. The Core will provide formalin fixed paraffin embedded samples of normal, adenoma and carcinoma to Project 2. In addition the Core will provide biospecimen qualification services, including but not limited to, histopathologic characterization of human and murine tissues treated with STAT3 inhibitor, and immunohistochemistry staining and interpretation, including validation of p-STAT3 staining by automated image analysis in a CLIA-certified facility. The Core will provide freshly resected PDAC samples for patient derived xenografts and ex vivo live tissue sensitivity assay (LTSA) for Project 3. In addition, the Core will provide histopathology characterization, immunohistochemistry services and interpretation guidelines for both preclinical samples from the ongoing co-clinical trials, as well as serial tissue biopsies obtained from the two clinical trials being conducted Project 3. The Core will also coordinate distribution of appropriate samples to investigators funded through the SPORE CEP and DRP grants. The Core personnel, along with the ITB, will enter detailed information related to all processes of biospecimen collection, processing, qualification, distribution and analytes extraction into the Institutional Biospecimen Informatics platform known as “Tissue Station”. The Core activities will lead to enhancement of these functionalities of Tissue Station and design a new interface specific for GI SPORE in the Tissue Station.